[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-349335-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-349335-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","co-targeting-cystathionine-gamma-lyase-and-mtor-a-promising-therapeutic-strategy-in-clear-cell-ovarian-cancer","Co-targeting cystathionine gamma-lyase and mTOR - a promising therapeutic strategy in clear cell ovarian cancer","","Clear cell ovarian carcinoma (CCOC) is a rare, aggressive subtype with poor outcomes driven by chemoresistance and frequent activating PIK3CA mutations that sustain PI3K/AKT/mTOR signaling and HIF1α expression. Despite pathway activation, mTOR inhibitors show limited clinical impact, and CCOC is treated similarly to other epithelial ovarian cancers. The study tests whether dual targeting cystathionine γ-lyase (CTH) and mTOR improves outcomes beyond mTOR inhibition alone. Using CCOC models under normoxia and hypoxia, combined therapy produces synergistic growth suppression and stronger effects on apoptosis, colony formation, spheroid size, and HIF1α downregulation.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/co-targeting-cystathionine-gamma-lyase-and-mtor-a-promising-therapeutic-strategy-in-clear-cell-ovarian-cancer/349335/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/co-targeting-cystathionine-gamma-lyase-and-mtor-a-promising-therapeutic-strategy-in-clear-cell-ovarian-cancer/349335.png","ImageObject",300,407,{"name":42,"@type":43},"Aran","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-30","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why were cystathionine γ-lyase (CTH) and mTOR targeted together in clear cell ovarian cancer?","Question",{"text":63,"@type":64},"CTH was identified as a metabolic vulnerability in CCOC that supports HIF1α expression, survival, and metastasis, while mTOR signaling is highly active yet mTOR inhibitors show limited efficacy. The study evaluated whether dual inhibition could outperform mTOR inhibition alone.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What experimental models and conditions were used to test the therapies?",{"text":68,"@type":64},"CCOC cell lines were engineered with CTH knockout or treated with a CTH inhibitor (Aviglycine hydrochloride), and mTOR was blocked with everolimus. Treatments were tested in 2D cultures and 3D spheroids under normoxia (21% O2) and hypoxia (1% O2), measuring viability, proliferation, colony formation, apoptosis, and protein signaling.",{"name":70,"@type":61,"acceptedAnswer":71},"What were the main results of combining CTH inhibition with mTOR inhibition?",{"text":72,"@type":64},"Everolimus alone modestly reduced viability and increased apoptosis. Adding CTH inhibition produced synergistic growth suppression, with stronger effects under hypoxia, reduced colony formation and spheroid size, increased caspase-3/7 activity, and greater HIF1α protein reduction while maintaining strong mTOR/S6 kinase pathway inhibition.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},349335,1790169572,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},137455076865,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Wei et al. BMC Cancer (2026) 26:761 BMC Cancer  \n[https://doi.org/10.1186/s12885-026-16092-1](https://doi.org/10.1186/s12885-026-16092-1)  \nRESEARCH Open Access  \nCo-targeting cystathionine gamma-lyaseand mTOR: a promising therapeutic strategy in clear cell ovarian cancer  \nLongyijie Wei1,2,3, Amal M. EL-Naggar 1,2,4*, Yuqin Li1,2, Yuchen Ding1,2, Eunice Li1, TszYin Lam1, Yemin Wang1,2, BusraTurgu1,2 and David G. Huntsman 1,2,3,5,6,7,8*  \nAbstract  \nClear cell ovarian carcinoma (CCOC) is a rare, aggressive ovarian cancer subtype, comprising approximately 12% of epithelial ovarian carcinoma (EOC) cases in Western countries yet associated with the worst prognoses due to its chemoresistance. Most CCOCs harbor activating PIK3CA mutations that drive PI3K/AKT/mTOR signaling and HIF1α expression. Despite their clinical success in some cancers, mTOR inhibitors have shown limited efficacy in CCOC, even though this pathway is highly active. Consequently, CCOC continues to be managed like other epithelial ovarian cancers. We recently uncovered cystathionine γ-lyase (CTH), a key enzyme in the transsulfuration pathway, as a metabolic vulnerability in CCOC, supporting HIF1α expression, survival and metastasis. This study aims to address whether simultaneously targeting CTH and mTOR could enhance therapeutic outcomes beyond those achieved by mTOR inhibition alone.  \nCCOC lines were engineered with CTH knockout (KO) or treated with the CTH inhibitor Aviglycine hydrochloride (AVG; ABG-3168); mTOR was blocked with everolimus, a clinical stage mTOR inhibitor. Single and combined treatments were tested in two-dimensional cultures and three-dimensional spheroids under normoxia (21% O2) and hypoxia (1% O2) . We measured viability, proliferation, colony formation, apoptosis, and protein signaling. Drug interaction was quantified with a synergy model.  \nEverolimus reduced viability and increased apoptosis across CCOC cell lines, but activity was modest as a single agent. Adding CTH inhibition produced synergistic growth suppression at low doses, with the effect being stronger under hypoxia. The combination reduced colony formation over 14 days and decreased spheroid size while increasing caspase-3/7 activity. Dual treatment decreased HIF1α protein expression more than either monotherapy while maintaining strong inhibition of mTOR/S6 kinase signaling; total mTOR and S6 kinase were unchanged. In CTH-deficient models, the synergy was maintained; however, pharmacological inhibition of CTH with AVG did not produce additional effects, indicating dependence on CTH activity and supporting an on-target mechanism. Similar antiproliferative effects with combined treatment were observed in a CTH-expressing Ewing sarcoma (EwS) model.  \n*Correspondence: Amal M. EL-Naggar  \n[aelnaggar@bccrc.ca](aelnaggar@bccrc.ca); [amal.elnaggar.ae@gmail.com](amal.elnaggar.ae@gmail.com)  \nDavid G. Huntsman  \n[david.huntsman@ubc.ca](david.huntsman@ubc.ca)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy ","cbCaifajmOCSnpyZ","https://ap.wps.com/l/cbCaifajmOCSnpyZ","pdf",8078220,17,"English","# Abstract\n## Experimental approach\n## Key findings and mechanistic insights\n## Background\n## Rationale for combination therapy","[{\"question\":\"Why were cystathionine γ-lyase (CTH) and mTOR targeted together in clear cell ovarian cancer?\",\"answer\":\"CTH was identified as a metabolic vulnerability in CCOC that supports HIF1α expression, survival, and metastasis, while mTOR signaling is highly active yet mTOR inhibitors show limited efficacy. The study evaluated whether dual inhibition could outperform mTOR inhibition alone.\"},{\"question\":\"What experimental models and conditions were used to test the therapies?\",\"answer\":\"CCOC cell lines were engineered with CTH knockout or treated with a CTH inhibitor (Aviglycine hydrochloride), and mTOR was blocked with everolimus. Treatments were tested in 2D cultures and 3D spheroids under normoxia (21% O2) and hypoxia (1% O2), measuring viability, proliferation, colony formation, apoptosis, and protein signaling.\"},{\"question\":\"What were the main results of combining CTH inhibition with mTOR inhibition?\",\"answer\":\"Everolimus alone modestly reduced viability and increased apoptosis. Adding CTH inhibition produced synergistic growth suppression, with stronger effects under hypoxia, reduced colony formation and spheroid size, increased caspase-3/7 activity, and greater HIF1α protein reduction while maintaining strong mTOR/S6 kinase pathway inhibition.\"}]","Co-targeting cystathionine gamma-lyase and mTOR - a promising therapeutic strategy in clear cell ovarian cancer | PDF",1790082842,43,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/054d49960d477336a283b6301d714517.webp",983,1310,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a7bd1ce9c465dfaeeb8e3d024dbea622.webp",982,1309,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bc7e3be40b1c2e62254a31f057746f45.webp",981,1308,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/548874a71f83fe08cdd4c20ff39bbfa5.webp",980,1306]